COMPANY NEWS

MyoStrain Featured in Four New Abstracts at German Society of Cardiology's 85th Annual Conference (DGK)

By Myocardial Solutions

/

April 28, 2019

MANHEIM, GERMANY, April 28, 2019 – Myocardial Solutions’ MyoStrain® was featured in four different abstracts presented at the 85th Annual Conference of the German Society of Cardiology (DGK). The event was held in Mannheim, Germany on April 24th-27th, 2019. The abstracts addressed the multiple uses for MyoStrain across indications covering the following topics:

  • A comparison of MyoStrain to left ventricular ejection fraction in their ability to detect subclinical cardiac dysfunction across various cardiac diseases
  • Using MyoStrain as a triage tool for patients with acute chest pain in the emergency room
  • The interim results of a study that used MyoStrain to detect cardiotoxicity from carfilzomib, an anti-cancer drug, in multiple myeloma patients
  • The opportunity to use MyoStrain for cardiac involvement in patients with Wilson’s disease

Links to the abstracts are provided below:

Title: Fast-SENC intramyocardial strain detects cardiac dysfunction before ejection fraction

Citation: Montenbruck M, et al.  Fast-SENC intramyocardial strain detects cardiac dysfunction before ejection fraction. DGK 2019. (n=674)

Title: Interim study: analysis of myocardial deformation using fSENC-CMR on patients with chest pain

Citation: Siry D, et al.  Interim study: analysis of myocardial deformation using fSENC-CMR on patients with chest pain.  DGK 2019. (n=20)

Title: Cardiac MRI for relapsed multiple myeloma patients: detection and prediction of cardiotoxicity related to Carfilzomib therapy

Citation: Nooman NA, et al.  Cardiac MRI for relapsed multiple myeloma patients: detection and prediction of cardiotoxicity related to Carfilzomib therapy.  DGK 2019. (n=8)

Title: Cardiac tissue characterization in patients with Wilson’s disease using cardiac magnetic resonance imaging

Citation: Salatzki J, et al.  Cardiac tissue characterization in patients with Wilson’s disease using cardiac magnetic resonance imaging. DGK 2019. (n=32)

Media Contact

Ahmed Osman
PR@myocardialsolutions.com
919.802.6411 

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.